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Objectives: This study aimed to determine the role of T1 mapping in identifying cardiac 
allograft rejection. 
Background: Endomyocardial biopsy (EMBx), the current gold standard to diagnose cardiac 
allograft rejection, is associated with potentially serious complications. Cardiovascular magnetic 
resonance (CMR)-based T1 mapping detects interstitial oedema and fibrosis, which are 
important markers of acute and chronic rejection. Therefore, T1 mapping can potentially 
diagnose cardiac allograft rejection non-invasively. 
Methods: Patients underwent CMR within 24 hours of EMBx. T1 maps were acquired at 1.5T. 
EMBx-determined rejection was graded according to International Society of Heart and Lung 
Transplant (ISHLT) criteria. 
Results: Of 112 biopsies with simultaneous CMR, 60 were classified as group 0 (ISHLT grade 
0), 35 group 1 (ISHLT grade 1R)), and 17 group 2 (2R, 3R, clinically diagnosed rejection, 
antibody-mediated rejection (AMR)). Native T1 values in patients with grade 0 biopsies and LV 
ejection fraction >60% (983 + 42ms (95% CI 972-994)) were comparable to non-transplant 
healthy controls (974 + 45ms, 95% CI 962-987). T1 values were significantly higher in group 2 
(1066 +78ms) vs. Group 0 (984 +42ms; p=0.0001) and vs. Group 1 (1001 + 54ms; p=0.001). 
After excluding patients with an eGFR <50 ml/min/m2, there was a moderate correlation of log 
transformed native T1 with hsTNT (r=0.54, p<0.0001) and pro-BNP (r=0.67, p<0.0001). Using a 
T1 cut off value of 1029ms, the sensitivity, specificity and negative predictive value were 93%, 
79% and 99% respectively. 
Conclusions: Myocardial tissue characterisation with T1-mapping displays excellent negative 
predictive capacity for the non-invasive detection of cardiac allograft rejection and holds promise 
to substantially reduce EMBx requirement in cardiac transplant rejection surveillance. 
 




CMR: Cardiavascular Magnetic Resonance 
EMBx: Endomyocardial Biopsy 
hsTNT: High sensitive troponin T 
Pro-BNP: Pro-brain type natriuretic peptide 
AMR: Antibody mediated rejection 
ECV: Extracellular volume 
eGFR: Estimated glomerular filtration rate. 
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Introduction: Acute allograft rejection remains one of the commonest complications in the first 
year after transplantation (1) with 20% of patients experiencing at least one episode of acute 
cellular rejection (ACR) in this period (1,2) and 10% of patients experiencing antibody mediated 
rejection (AMR) (3). Acute allograft rejection often results in allograft dysfunction and is one of 
the main determinants of mortality and morbidity in early post-transplant period (1). Moreover, 
recurrent and chronic rejection leads to allograft vasculopathy, one of the commonest indications 
for redo-transplantation (4-7). Therefore, accurate and timely diagnosis of allograft rejection is 
paramount to enable early and effective treatment. 
Histological analysis of an endomyocardial biopsy (EMBx) is the current gold standard for the 
diagnosis of cardiac allograft rejection. Many transplant centres have intense surveillance 
programs with recipients undergoing 12-15 biopsies in first 12 months. An EMBx is an invasive 
procedure associated with a 3-6% risk of serious complications including carotid artery puncture, 
pneumothorax, tricuspid regurgitation, cardiac arrhythmias and cardiac tamponade (8-11). 
Furthermore, EMBx and histological analysis are neither very accurate nor reproducible with 
high false positive and false negative results reported because of sampling error and inter- 
observer variability (12-14). Therefore, an alternative diagnostic strategy is required which is 
less invasive and more accurate. 
Cardiovascular magnetic resonance imaging (CMR) is non-invasive and has the capacity to 
assess regions of myocardium not accessible to EMBx. T1- and T2-mapping imaging sequences 
enable accurate and reproducible detection of myocardial interstitial oedema and fibrosis (15- 
19). Their role in the detection and monitoring of acute myocarditis and myocardial ischemia is 
well established (15-18). Studies have also demonstrated the role of T1 mapping in the detection 
of interstitial myocardial fibrosis in scleroderma, rheumatoid arthritis and in the post-myocardial- 
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infarction setting (20-22). Interstitial edema is also an important marker of acute allograft 
rejection (23,24), whilst interstitial fibrosis is a hallmark of low-grade chronic rejection (25). We 
hypothesized that CMR would detect acute cardiac allograft rejection and studied the role of T1 
mapping in the diagnosis and management of allograft rejection in heart transplant recipients. 
Methods: 
 
Patients and study design: 
 
In this observational, prospective cross-sectional study, all patients undergoing heart 
transplantation from 1st April 2014 to 31st December 2015 at a single centre were screened. 
Exclusion criteria were standard contraindications to CMR including claustrophobia and inability 
to lie supine. The study was approved by the St. Vincent’s Hospital Human Research Ethics 
Committee, Sydney, New South Wales, Australia (HREC/13/SVH/66). All patients gave written 
informed consent. All CMRs were performed within 24 hours of routine surveillance cardiac 
biopsies at 6, 8, 10, 12, 20, 24, 32 and 52 weeks after transplantation. If patients had clinically 
significant rejection as determined by histology, CMR was repeated along with the repeat biopsy 
after a course of treatment with pulse immunosuppressive therapy. Six patients in the cohort also 
underwent a non-routine cardiac biopsy based on clinical suspicion of rejection by an 
independent transplant physician and were also recruited into the study. 
Serum highly sensitive troponin T (hsTNT) and pro-brain type natriuretic peptide (pro-BNP) 
were also measured within 24 hours of cardiac biopsies. 
Non-transplant patients without any background cardiac history and a low pre-test probability of 
cardiomyopathy who were referred to our centre for CMR for non-specific symptoms and were 
reported to have a normal CMR by an independent specialist were used for comparison. 
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CMR acquisition: CMR studies were performed on a 1.5 T scanner (Achieva, Philips Medical 
 
Systems, Best, Netherlands) equipped with a 32-channel coil. Steady-state free precession 
(SSFP) cine images in standard long-axis (4, 3 and 2 chamber) and short axis views were 
performed. (26-28). An SSFP, single breath-hold, Modified Look-Locker Inversion recovery 
(MOLLI) sequence was used to acquire T1 maps in a single mid-ventricular short axis plane (FA 
500, voxel size 1.8 x 1.8 x 8.0mm, 8 images from two adiabatic pre-pulse induced inversions 
(3,(2),5))(29,30). Intravenous gadobutrol (Bayer Healthcare, Leverkusen, Germany) was 
administered in dose of 0.1 mmol/kg per body weight, as per the local clinical protocol only to 
those patients whose estimated glomerular filtration rate (eGFR) was greater than 40ml/min/1.73 
m2. T1 maps were also acquired twenty minutes after contrast administration. The hematocrit 
was measured within 24 hours of CMR to calculate extracellular volume (ECV) as previously 
described (31,32). 
CMR analysis: All CMR images were analysed using commercially available software (CMR42, 
 
Circle Cardiovascular Imaging, Inc., Calgary, Canada). Regions of interest were drawn along the 
interventricular septum as well as circumferentially in mid-ventricular short axis slice to acquire 
septal and global T1 values (26-28,33) (Figure 1a). Care was taken to avoid the endo- and 
epicardium. After manual motion correction of each individual image, septal and global T1 
values were calculated by fitting an exponential model to data from eight images at different 
inversion times (26-28,30,33). Myocardial partition coefficients (λ) and extracellular volume 
fractions (ECV) were calculated as previously described (λ = ΔR1myocardium/ΔR1blood; ECV 
= λ (1 − haematocrit)) (32). 
 
Cardiac biopsies: The endomyocardial cardiac biopsies were performed from a right internal 
 
jugular approach. Biopsies were stained with haematoxylin and eosin and were reported by an 
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anatomical pathologist blinded to CMR results. The biopsies were graded as 0, 1R, 2R or 3R in 
accordance with International Society of Heart & Lung Transplantation (ISHLT) criteria (24). 
Patients who were diagnosed with antibody mediated rejection (AMR) based on a combination 
of clinical suspicion, allograft dysfunction, serological and tissue markers (C4d staining on 
immunohistochemistry and elevated donor-specific antibodies) were also included. Patients who 
were treated for clinically-diagnosed rejection by an independent physician because of a high 
clinical index of suspicion based on signs and symptoms of rejection including chest pain, 
palpitations, dyspnoea, weight gain, ankle edema, along with decline in echocardiography- 
derived LV ejection fraction despite bland biopsies were also included. 
In asymptomatic patients, pulse immunosuppressive therapy is generally indicated for ISHLT 
grade 2R, 3R or AMR (34), therefore, the cohort was grouped into three pre-specified groups, 
Group 0= ISHLT grade 0, Group 1= ISHLT grade 1R, Group 2= grade 2R, 3R, AMR and 
clinically diagnosed rejections. 
Cardiac biopsies were also stained with Masson’s trichrome stain to quantify fibrosis using semi- 
automated purpose-designed local software (Figure 1b & 1c). 
Statistical analysis: Statistical analysis was performed using GraphPad Prism® 7.00 (GraphPad 
 
Software, Inc., La Jolla, CA, USA) and Microsoft Excel. Categorical data is expressed as number 
and percentage while continuous variables as mean + SD. A p value of < 0.05 was considered 
significant. For the comparison of normally distributed variables, unpaired student t-test, paired 
t-test, analysis of variance-ANOVA and Tukey`s multiple comparisons tests were used as 
appropriate. Correlation was measured using Pearson’s coefficient. Nineteen randomly selected 
CMRs were used for inter-observer variability using Bland & Altman plots and coefficients of 




A total of 169 scans were performed (118 biopsy-matched CMRs in 34 heart transplant 
recipients and 51 CMRs in non-transplant healthy controls; Table 1). Logistic limitations 
(scanner access) prevented some patients having concurrent CMRs. Six scans were excluded, 
one due to significant motion artefact on CMR, one due to inadequate tissue sampling on biopsy, 
one due to the presence of severe mitral regurgitation and three because patients could not lie flat 
long enough to perform T1 mapping. Eighty-nine percent of the scans were performed within the 
first-year after transplantation. Twelve scans (11%) were performed more than 12 months post 
transplantation along with clinically-indicated biopsies. 
Of 112 biopsies with simultaneous CMR, 60 (54%) demonstrated no rejection (Group 0 (ISHLT 
grade 0)), 35 (31%) demonstrated only mild rejection (Group 1 (ISHLT grade 1R)), and 17 
(15%) demonstrated clinically-significant rejection requiring pulse immunosuppression (Group 2 
(2R, 3R, clinically diagnosed rejection, AMR, and 2R on a repeat biopsy after recent pulse 
immunosuppression). Out of 34 patients, seven patients had clinically significant rejections. The 
majority of rejections occurred in first 12 months (n=12), while two occurred in one patient in 
the second year after transplantation (3R & 2R) and three rejection episodes (two AMR and one 
clinically diagnosed) in another patient more than 5 years post-transplantation (Patients 5 & 1 
respectively in supplementary material). 
Normal T1 values in Heart Transplantation: 
 
To establish normal native T1 values in heart transplant patients, patients with both ISHLT grade 
0 biopsies and a LV ejection fraction >60% were selected (Table 2). Their mean T1 value was 
marginally higher compared to non-transplant healthy controls (983 + 42ms vs 974 + 45ms; 
p=0.30) with no statistically significant difference (Figure 2a). Their septal T1 values were 
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higher than global T1 values (983 + 42ms vs 969 + 39ms; p<0.0001); the difference was small, 
 
though statistically significant (Figure 2b). There was no significant correlation between native 
T1 values and donor age, sex, time post-transplantation or transplant-procedure ischemic time 
(Figure 2c, 2d). 
Native T1 Across Rejection Groups: 
 
Comparing across various rejection groups, the native T1 values were significantly higher in 
patients with clinically significant rejection: Group 2 (1066 +78msc) vs. Group 0 (984 +42ms; 
p=0.0001) and vs. Group 1 (1001 + 54msec; p=0.001) (Figure 3a, Table 3). There was no 
 
statistically significant difference between group 0 and group 1. On comparison of individual 
rejection grades and rejection types, T1 values were significantly higher in both AMR (1137 + 
25ms) and grade 2R/3R (1091 + 97ms) compared to grade 0 (984 +42msec; p=0.0001) and 1R 
 
(1001 + 54msec; p=0.001) (Figure 3b). The values were also significantly higher in patients with 
clinically diagnosed rejection (1052 +11ms) compared to grade 0 (P=0.01) but this difference 
was not statistical significant compared to grade 1R. The patients who still had grade 2R 
rejection on biopsy within 1-3 weeks of treatment with pulse immunosuppressive therapy for 
grade 2R/3R had lower T1 values (969 +10ms) compared to grade 2R/3R ( p=0.001) and AMR 
(p=0.0001). 
 
Comparing septal and global T1 values within each individual rejection group, there was no 
statistically significant difference between measurement techniques (Figure 3c). 
 
 
Analysis of repeated-observations have been made in the small subset of patients who have 
experienced significant rejection. To account for this, we have also analysed the data by selecting 
only the first episode of each rejection grade within individual patients. This reduced the total 
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number of biopsies to 55 in 34 patients with simultaneous CMR. Twenty-seven (49%) biopsies 
demonstrated no rejection (Group 0 (ISHLT grade 0)), 18 (33%) demonstrated only mild 
rejection (Group 1 (ISHLT grade 1R)), and 10 (18%) demonstrated clinically-significant 
rejection requiring pulse immunosuppression (Group 2 (2R, 3R, clinically diagnosed rejection, 
AMR, and 2R on a repeat biopsy after recent pulse immunosuppression). The native T1 value 
were still significantly higher in patients with clinically significant rejection: Group 2 (1088 + 
87ms) vs. Group 0 (977 + 46ms; p<0.0001) and vs. Group 1 (1007 + 56ms; p=0.003) 
 
(Supplementary Figure 3). 
 
Tracking response to pulse immunosuppression with T1 mapping: 
 
Six patients with significant rejection underwent serial studies. Native T1 mapping values were 
increased during acute rejection episodes (1093 + 76) and reduced significantly after pulse 
immunosuppressive therapy in all but one patient (996 + 43) (p=0.02, paired T-test; Figure 3d, 
 
supplementary Figures 1 & 2). 
 
Comparison of Extracellular volume (ECV) fraction with rejection groups and interstitial fibrosis 
 
Intravenous contrast was administered in 21 patients with 51 CMRs to measure extracellular 
volume fraction. Numbers were significantly smaller than the cohort size due to renal 
impairment, which occurs commonly after heart transplantation (albeit often transiently due to 
medication side-effects). There was no statistical difference between rejection groups, however, 
interpretation is significantly limited by the small sample size (only four CMRs were performed 
with contrast during periods of significant rejection). 
The degree of fibrosis was measured in tissue sample using Masson’s trichrome stain and semi- 
automated software. There was no significant correlation between ECV and degree of fibrosis 
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(r=0.20, P= 0.22) (Figure 4a). Comparing native T1 values with degree of fibrosis, there was 
weak, non statistically-significant correlation (r=0.21, P=0.051) (Figure 4b). 
Comparison of native T1 with different parameters: 
 
Both left ventricular ejection fraction (LVEF) and mass were weakly correlated with native T1 
(LVEF vs T1: r=0.22, P=0.02; LV mass vs T1: r=0.22, P=0.02). There was a modest correlation 
between log transformed native T1 and hsTNT (r=0.34, p=0.001) as well as pro-BNP (r=0.61, 
p<0.0001) (Figure 4c, 4e). After excluding patients with an eGFR <50 ml/min/m2, this 
correlation improved (log T1 vs log hsTNT: r=0.54, p<0.0001; logT1 vs log pro-BNP: r=0.67, 
p<0.0001) (Figure 4d, 4f). 
Native T1 Specificity and Sensitivity: 
 
After plotting native T1 values on a Receiver Operator Curve (ROC), the area under the curve 
(AUC) was 0.89. Using a T1 value of 1029ms as a cut off, the sensitivity for detecting clinically 
significant rejection was 93%, with a specificity of 79% and negative predictive value of 99% 
(Figure 5a). Nineteen CMRs were randomly selected and native T1 mapping values were 
measured by two independent CMR physicians. The inter-observer variability was measured 
using Bland-Altman method of comparison (Figure 5b). The coefficient of variance was 1.3%. 
Discussion: 
This study explores the role of CMR-based myocardial T1 mapping in heart transplantation and 
demonstrates that T1 mapping is highly sensitive for the diagnosis of clinically significant 
cardiac allograft rejection and is able to track recovery after pulse immunosuppressive therapy. 
Most studies to date focussing on the role of CMR in heart transplantation have used less 
reproducible sequences to define edema and fibrosis including STIR (Short Tau Inversion 
Recovery sequence), T1-weighted spin-echo sequence for global relative enhancement (gRE) 
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and LGE (late gadolinium ehancement (35) or recruited patients more than six months after 
transplantation, missing the most critical period to diagnose rejection(36). A recent study by 
Miller et al. using T1 mapping demonstrated a trend towards increased T1 values in patients with 
rejection but did not achieve statistical significance (37). Our study utilised a well-validated T1 
mapping sequence (17) and recruited patients from 6 weeks post transplantation (average time 
from transplant date to 1st CMR was 10 weeks); and majority of the scans (n=61, 55%) were 
performed in first 6 months after transplantation. 
This study establishes a normal T1 mapping range for heart transplant recipients using a widely 
available MOLLI sequence. We found that the normal native T1 value in heart transplant 
recipients with histological grade 0 rejection (and normal LVEF) was 983 + 45 ms which is 
comparable to our non-transplant healthy controls (974 + 42 ms) and established normal values 
 
in the literature (30). 
 
Native T1 values were significantly higher in patients with clinically significant rejection 
compared to those with non-clinically-signficant or no rejection. T1 mapping values in the non- 
transplant population are elevated in conditions with known extracellular space expansion 
secondary to both oedema and interstital fibrosis (15-18,21,22). Myocardial edema is an 
important pathological marker of acute allograft rejection (23). To help determine whether the 
native T1 value represented edema or fibrosis, we quantified the degree of fibrosis using a 
Masson’s trichrome stain. Only a weak correlation was observed between T1 values and 
histologically quantified fibrosis (non-statistically significant), suggesting the majority of T1 
change was attributable to interstitial edema rather than fibrosis. It is also important to note that 
patients can develop scar tissue due to repetitive biopsy from the same site reducing the accuracy 
of the association. 
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A subset of patients with ISHLT grade 1R rejection (mild) had elevated markers of myocardial 
injury (hsTNT and pro- BNP). These markers correlated fairly well with T1 values but not with 
ISHLT rejection grade. This suggests that some patients are experienceing low-grade active 
myocardial damage and edema, potentially missed by histological grading. A prospective 
randomized outcome study comparing T1 mapping and cardiac biopsies would help determine 
the clinical relevance of this discrepancy. 
Using a T1 cut-off 1029 ms, we demonstrate high sensitivity (93%) and adequate specificty 
(79%) with an excellent negative predicitve value (99%). In our study we missed only one 
significant episode of ISHLT Grade 2R rejection. In contrast to the other patients with clinically 
significant rejection, no change in T1 value or LVEF was observed after the administration of 
pulse corticosteroids in this patient, bringing into question the accuracy of the histological 
diagnosis. Comparison to the current gold standard, EMBx, was employed in this study, 
however, future prospective randomised studies with outcome endpoints will better determine 
the best way to diagnose and track cardiac allograft rejection. Notwithstanding, the majority of 
biopsies in our cohort (85%) displayed no clinically significant rejection and T1 mapping has 
promise to dramatically reduce the number of survellance cardiac biopsies in the first year after 
transplantation. 
All patients with AMR or ISHLT Grade 3R rejection had values higher than 1100ms. All 
patients with grade 2R or clinically-diagnosed rejection had values in the range of 1030-1070ms 
with the exception of the one patient mentioned above. This suggests that future larger studies 
may be able to determine T1 based cut-off values that prompt further investigation for AMR, a 
condition which is notoriously difficult to diagnose and requires tailored immunosupression. 
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Although there was no statistically significant difference in ECV values between groups, the 
sample size was too small to draw any conclusions. Due to the high prevalence of renal 
impairment (>50%), it is unlikely that ECV measurement, which requires gadolinium contrast 
administration, is a practical method for determining myocardial expansion in this cohort. 
Our study also demonstrates that native T1 mapping tracks recovery from clinically-significant 
rejection after pulse immunosuppressive therapy. T1 values fell from elevated levels in patients 
with clinically significant rejection after therapy. Furthermore, a hypothesis-generating finding 
of our study was that several patients had normalised their T1 values after pulse 
immunosuppressive therapy despite a persistent ISHLT Grade 2R on their serial biopsy. This 
suggests that perhaps the histopathological recovery may lag behind the reduction in CMR- 
determined myocardial edema. 
Limitations: 
 
One hundred and two scans (93%) were performed within 24 hours of cardiac biopsy whilst 8 
CMRs were performed just outside the pre-specified 24 hr period due to logistic reasons. None 
of these biopsies revealed significant rejection and none of these patients had any pulse 
immunosuppression or change in their immunosuppressive therapy between cardiac biopsy and 
CMR. The prospective, observational study was conducted over a relatively short period of 12 
months. The sample size is relatively small, although not unreasonable for a transplant 
population. Cardiac biopsies were used as the gold standard comparator for T1 mapping; 
however, it is well recognized that this has poor reproducibility with high inter-observer 
variability. Cardiac biopsies were taken from the right ventricular septal endocardium, whereas, 
T1 mapping regions of interest were placed in the mid-wall to avoid blood-pool artefact. A 
prospective randomized study with morbidity and mortality endpoints is required to further 
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T1 mapping is highly sensitive for the diagnosis of clinically significant cardiac allograft 
rejection and tracks recovery after pulse immunosuppressive therapy. The technique 
demonstrates excellent interobserver reproducibility and holds promise to be a routine non- 





Competency in Patient Care and Procedural Skills: 
 
Our research demonstrates that the use of non-invasive and highly reproducible native T1- 
mapping is able to substantially reduce the number of routine surveillance cardiac biopsies after 
cardiac transplantation and therefore, can improve overall patient care. 
Translational Outlook: 
 
This study warrants a prospective randomised control trial using mortality and morbidity 
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Figure 1: T1 mapping and cardiac biopsy with Masson`s trichrome stain. 1a. Mid- 
ventricular short axis slice demonstrating calculation of septal (orange) and global (blue) T1 
values. 1b. Cardiac biopsy with Masson`s Trichrome stain for fibrosis. 1c. Processed image in 
semi-automated purpose designed software to quantify fibrosis. 
 
Figure 2: Scatter plots for T1 values in normal heart transplant population (ISHLT grade 0 
with left ventricular ejection fraction > 60%). 2a. Heart transplant grade 0 vs non-transplant 
healthy controls (p= 0.30). 2b. Septal T1 vs global T1 (p<0.0001). 2c. Correlation of T1 with 
time post-transplantation (p= 0.64). 2d. Correlation of T1 with transplant-procedure ischaemia 
time (p=0.75). HTx grade 0: Heart transplant patients with grade 0. ISHLT: International Society 
of Heart and Lung Transplantation. 
 
Figure 3: T1 values across various rejection types. 3a. Comparison of T1 in group 2 (1066 
+78msec) with group 0 (984 +42msec; p=0.0001) and group 1 (1001 + 54msec; p=0.001). Group 
0= ISHLT Grade 0; group 1= ISHLT grade 1R; group 2 (clinically significant rejection) = Grade 
2R, 3R, AMR and clinically diagnosed rejections). 3b. Comparison of T1 across various 
rejection grades and types; AMR= antibody mediated rejection, (1137 + 25mec) and ISHLT 
grade 2R/3R (1091 + 97msec) had significantly high T1 values compared to ISHLT grade 0 (984 
+42msec; p=0.0001) and ISHLT grade 1R (1001 + 54msec; p=0.001).  Clin= clinically 
diagnosed rejection (1052 +11msec) had significantly higher T1 values compared to ISHLT 
grade 0 (p=0.01). 2R/PRx= Patients with grade 2R rejection on biopsy within 1-3 weeks of 
treatment for grade 2R/3R, (969 +10msec). 3c. Comparison of septal and global T1 values within 
each rejection group. 3d. Comparison of native T1 mapping values during acute rejection 
episodes (1093 + 76) and post pulse immunosuppressive therapy (PRx=996 + 43; p=0.02) using 
paired T-test. 
 
Figure 4: Correlation of T1 with fibrosis, troponin and Pro-BNP. 4a. Degree of fibrosis vs 
ECV (r=0.20, P= 0.22). 4b. Degree of fibrosis vs T1 (r=0.21, P=0.051). 4c. log T1 vs log hsTNT 
in all patients (r=0.34, p=0.001). 4d. log T1 vs log hsTNT in patients with eGFR >50 ml/min/m2 
(r=0.54, p<0.0001). 4e. log T1 vs log pro-BNP in all patients (r=0.61, p<0.0001). 4f. log T1 vs 
log pro-BNP in patients with eGFR >50 ml/min/m2 (r=0.67, p<0.0001). ECV= extracellular 
volume; hsTNT= High sensitive troponin T; pro-BNP= Pro-brain type natriuretic peptide. 
 
Figure 5: Sensitivity, specificity and inter-observer variability of T1 mapping. 5a. A 
Receiver Operator Curve (ROC) for T1 mapping (using 1029msec as a cut off, the sensitivity 
=93%; specificity =79%; negative predictive value of 99%, AUC 0.89). 5b. Bland & Altman 
plots for inter-observer variability of T1 mapping. 
 
Table 1: Patients` characteristics 
 
 





No. of scans (113) 51 112  
Sex (%)    
Male 51 59 
Female 49 41 
Age (years) 46 + 14 36 + 14  
Height (m) 1.72 + 0.10 1.75 + 0.6  
Weight (Kg) 78 + 13 86 + 14  
Body Mass Index (BMI)  28 + 5  
Left ventricular ejection fraction (EF %) 58 + 18 68 + 9  
Left ventricular mass (g) 166 + 75 144 + 30  
Ischaemia time (mins)  205+ 100 0.2 




Mean time to recruitment (Months post- 
 





CMRs > 12 months post- transplantation 
 
(n=12) 
 11%  
Mean time between CMR and EMBx 
 
(hours) 
 19 + 68 <0.0001 
No. of scans per patient  3 + 2 0.01 
CMV status    
 Positive 8 (7%) 
 Negative 40 (36%) 
 
 Unknown  64 (57%)  
eGFR (ml/min/1.73m2)  60 + 19 >0.100 
Rejection grades    
 Grade 0 60 (54%) 
 Grade 1R 35 (31%) 
 Grade 2R/3R 6 (5%) 
 AMR 3 (2.5%) 
 Clinically diagnosed rejections 5 (4.5%) 
 2R post treatment (PRx)† 3 (3%) 
Immunosuppression at time of EMbx:    
 MMF/TAC/Prednisolone 64 (57%) 
 MMF/RAD/TAC/Prednisolone 42 (38%) 
 MMF/Cyclosporine/Prednisolone 2 (2%) 
 MMF/Cyclosporine/RAD/prednisolone 4 (3%) 
EMBx= endomyocardial biopsy; CMV= Cytomegalovirus; eGFR= estimated glomerular filtration rate; 
AMR= antibody mediated rejection; MMF= Mycophenolate; TAC= Tacrolimus; RAD= Everolimus 
†Biopsies with grade 2R rejection within 1-3 weeks of pulse immunosuppressive therapy 
 
Table 2: Normal T1 Values in Heart Transplant Patients 
 
 
 Heart transplant grade 
 









983 + 42 
 





981 + 45 (n=36)* 
 
986 + 36 (n=20)† 
 0.65 
‡0-3 Months (n=16) 
 
3-6 Months (n=19) 





6-12 Months (n=13) 
 
> 12 Months (n=5) 
976 + 26 
 
959 + 50 
  





Table 3: Comparison of different parameters across various rejection groups 
 
 










Septal T1 (msec) 984 +42 1001 + 54 1066 +78 0.0001 
Global T1 (msec) 970 +41 993 +50 1052 + 69 0.0001 
LVEF (%) 67 + 10 72 + 6 65 + 12 0.01 
LV mass (gm) 145 + 24 141 + 31 154 +40 0.30 
ECV 0.35 + 0.05 
 
(n=31) 
0.39 + 0.10 
 
(n=16) 
0.38 + 0.03 (n=4) 0.22 
hsTNT 41 +51 (n=38) 61 + 47 (n=20) 63 + 50 (n=15) 0.23 
 
 
Group 0= ISHLT Grade 0; group 1= ISHLT grade 1R; group 2= Grade 2R, 3R, antibody mediated 
rejection (AMR) and clinically diagnosed rejections. ECV= extracellular volume; LVEF= left ventricular 

















































Supplementary Figure 1: Role of T1 mapping in tracking response to pulse immunosuppressive 
therapy. Comparison of T1 values in post-treatment group (PRx=975 msec + 30) with non-rejection 




Supplementary Figure 2. Serial T1 values in individual patients with significant rejection. 
 
Native T1 values in Individual Patients with Clinically Significant Rejection: 
 
Patient 1 had a normal T1 value (965ms) with grade 2R histological rejection. After pulse 
immunosuppressive therapy, the histological grade improved to 1R while T1 value remained normal 
(970ms). Similarly, patient 3 had a decline in left ventricular ejection fraction, and was diagnosed to 
have rejection on a clinical basis without histological evidence. This patient was managed more 
conservatively with an increase in immunosuppression (without pulse steroids) until cardiac biopsy 
finally revealed grade 2R rejection. At this stage the patient was pulsed with steroids and the T1 
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Supplementary Figure 3: T1 values across various rejection types by selecting only first episode of 
each rejection type within individual patients. Group 2 had high native T1 values (1088 + 87ms) 











Grade 0; group 1= ISHLT grade 1R; group 2 (clinically significant rejection) = Grade 2R, 3R, AMR and 
clinically diagnosed rejections). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
